FRANK ANTONAWICH, Ph.D. received his B.S. Degree in Neuroscience from the University of Rochester, New York in 1988. His graduate studies were completed in Dr. Fleur Strand’s Laboratory of Physiology and Neuroendocrinology at New York University. As a Graduate Assistant he studied the effects of heavy metals on neoplasms in the Department of Pathology.
His graduate Fellowship was conducted in the Department of Biology and Center for Neuroscience at New York University, where he studied the protective effects of peptides and hormones on brain injury and was awarded his Ph.D. in 1994. Dr. Antonawich was awarded the Charlotte Pann Award for the most outstanding Thesis, as well as the Gladys Mateko Award, presented to the top graduate student in the program. He continued at the University as an Adjunct Professor of Biology teaching Advanced Physiology and Neuroendocrinology courses in the Graduate School.
In 1994, Dr. Antonawich was awarded a National Institute of Health Post Doctoral Fellowship in Neurology from the State University of New York at Stony Brook. From 1995–1997, he was awarded a second National Institute of Health Fellowship to study the programmed cell death (apoptosis) associated with stroke and ischemia. He continued his Neurodegeneration Work during his Post-Doctoral Fellowship in Dr. James Davis’ Laboratory and became an Assistant Professor of Neurology in 1997 and taught in the Department of Pharmacology at Stony Brook.
Dr. Antonawich has numerous publications in peer-reviewed Journals, and has written multiple chapters for books as well. His research over the past decade examines the role of cellular energy in the diseased states of cancer and stroke. This has led to his extensive studies using the unique dietary supplement Poly-MVA. Its most active ingredient is a Palladium Lipoic Acid Complex (PdLA) where the element palladium is bound to the anti-oxidant alpha-lipoic acid resulting in a potent anti-oxidant and energy facilitating formulation. His ishemia/stroke studies have demonstrated that acute, post-ischemic and prophylactic administration of Poly-MVA limits ischemic damage. Furthermore, due to the metabolic dysfunction of cancer cells, Poly-MVA’s energy initiates cell death in malignant cells.
He will speak on Poly-MVA For Cancer & Stroke.